Pub Date : 2022-10-01DOI: 10.1136/ijgc-2022-esgo.878
Susana Banerjee, T. André, D. Berton, S. Ellard, B. Jímenez, V. Samouëlian, L. Gilbert, V. Boni, Xinwei Han, G. Antony, J. Veneris, A. Oaknin
with mismatch repair deficient (dMMR) recurrent/advanced endometrial cancer (EC) that has progressed on or after platinum-based chemotherapy or solid tumours that have progressed on or after prior treatment, with no satisfactory alternative treatment options. We report a post hoc analysis of antitumour activity by PDL1 expression and tumour mutational burden (TMB) in patients with dMMR and MMR proficient (MMRp) solid tumours in the GARNET trial.
{"title":"2022-RA-945-ESGO Antitumour activity of dostarlimab by PD-L1 and tumour mutation burden in patients with mismatch repair deficient and proficient tumours in the GARNET trial","authors":"Susana Banerjee, T. André, D. Berton, S. Ellard, B. Jímenez, V. Samouëlian, L. Gilbert, V. Boni, Xinwei Han, G. Antony, J. Veneris, A. Oaknin","doi":"10.1136/ijgc-2022-esgo.878","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.878","url":null,"abstract":"with mismatch repair deficient (dMMR) recurrent/advanced endometrial cancer (EC) that has progressed on or after platinum-based chemotherapy or solid tumours that have progressed on or after prior treatment, with no satisfactory alternative treatment options. We report a post hoc analysis of antitumour activity by PDL1 expression and tumour mutational burden (TMB) in patients with dMMR and MMR proficient (MMRp) solid tumours in the GARNET trial.","PeriodicalId":406851,"journal":{"name":"Translational research/biomarkers","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126961304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-01DOI: 10.1136/ijgc-2022-esgo.868
Arturas Dobilas, P. Leandersson, Yilun Chen, M. Alcaide, C. Brueffer, L. Saal, C. Borgfeldt
2022-RA-627-ESGO Figure 1 Waterfall plot of validated somatic mutations in the patient tumors. Genes are indicated in rows and samples in columns. Mutated samples are show according to mutation type. Patient and tumor clinopathological variables are shown below the patient IDs Abstract 2022-RA-627-ESGO Figure 2 Plasma circulating tum or (ctDNA) mutant concentration increased with higher stage (ptrend<0.001).Concentrations of circulating tumor DNA (ctDNA) in stage III and stage IV OvCa were significantly higher compared with stage I OvCa (p=0.025 and p=0.007 respectively) Bars include highest and lowest values, except outliers (o), which are 1.5 to 3 box lengths from the end of the box, and extremes (*) which are more than 3 box lengths from the end of the box2022-RA-627-ESGO Figure 2 Plasma circulating tum or (ctDNA) mutant concentration increased with higher stage (ptrend<0.001).Concentrations of circulating tumor DNA (ctDNA) in stage III and stage IV OvCa were significantly higher compared with stage I OvCa (p=0.025 and p=0.007 respectively) Bars include highest and lowest values, except outliers (o), which are 1.5 to 3 box lengths from the end of the box, and extremes (*) which are more than 3 box lengths from the end of the box Conclusion Measuring ctDNA in pre-operative plasma may be useful as a predictive biomarker for tumor staging and prognosis in ovarian cancer patients. Abstracts Int J Gynecol Cancer 2022;32(Suppl 2):A1–A504 A405 on D ecem er 8, 2022 by gest. P rocted by coright. http/ijgc.bm jcom / nt J G ynecol C acer: frst pulished as 10.11ijgc-2022-E S G O .68 on 20 O cber 222. D ow nladed fom
图1患者肿瘤中验证体细胞突变的瀑布图。基因以行表示，样本以列表示。根据突变类型显示突变样本。患者和肿瘤的临床病理变量显示在患者id下面。摘要:图2血浆循环周期或(ctDNA)突变体浓度随着分期的增加而增加(p趋势<0.001)。浓度的循环肿瘤DNA (ctDNA)在第三阶段和第四阶段与阶段相比我OvCa OvCa显著高于(p = 0.025, p = 0.007)酒吧包括最高和最低值,除了离群值(o), 1.5到3盒的长度从结束的盒子,和极端(*)超过3箱长度从box2022结束- ra - 627 esgo图2血浆循环tum或(ctDNA)突变体浓度增加与高级阶段(ptrend < 0.001)。III期和IV期OvCa的循环肿瘤DNA (ctDNA)浓度显著高于I期OvCa (p=0.025和p=0.007)。条形图中包括最高值和最低值，除了离箱端1.5 - 3个箱长的异常值(o)。结论术前血浆ctDNA检测可作为卵巢癌患者肿瘤分期和预后的一种预测性生物标志物。[J] journal of Gynecol Cancer, 2022;32(增刊2):A1-A504 A405 on D，预计于2022年8月8日公布。P由赖特保护。http / ijgc。jj.com / nt jgynecol C acer:首次发表于222年12月20日，号10.11ijgc-2022-E S G O .68。我们从
{"title":"2022-RA-627-ESGO Preoperative circulating tumor DNA level is associated to poor overall survival in patients with ovarian cancer","authors":"Arturas Dobilas, P. Leandersson, Yilun Chen, M. Alcaide, C. Brueffer, L. Saal, C. Borgfeldt","doi":"10.1136/ijgc-2022-esgo.868","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.868","url":null,"abstract":"2022-RA-627-ESGO Figure 1 Waterfall plot of validated somatic mutations in the patient tumors. Genes are indicated in rows and samples in columns. Mutated samples are show according to mutation type. Patient and tumor clinopathological variables are shown below the patient IDs Abstract 2022-RA-627-ESGO Figure 2 Plasma circulating tum or (ctDNA) mutant concentration increased with higher stage (ptrend<0.001).Concentrations of circulating tumor DNA (ctDNA) in stage III and stage IV OvCa were significantly higher compared with stage I OvCa (p=0.025 and p=0.007 respectively) Bars include highest and lowest values, except outliers (o), which are 1.5 to 3 box lengths from the end of the box, and extremes (*) which are more than 3 box lengths from the end of the box2022-RA-627-ESGO Figure 2 Plasma circulating tum or (ctDNA) mutant concentration increased with higher stage (ptrend<0.001).Concentrations of circulating tumor DNA (ctDNA) in stage III and stage IV OvCa were significantly higher compared with stage I OvCa (p=0.025 and p=0.007 respectively) Bars include highest and lowest values, except outliers (o), which are 1.5 to 3 box lengths from the end of the box, and extremes (*) which are more than 3 box lengths from the end of the box Conclusion Measuring ctDNA in pre-operative plasma may be useful as a predictive biomarker for tumor staging and prognosis in ovarian cancer patients. Abstracts Int J Gynecol Cancer 2022;32(Suppl 2):A1–A504 A405 on D ecem er 8, 2022 by gest. P rocted by coright. http/ijgc.bm jcom / nt J G ynecol C acer: frst pulished as 10.11ijgc-2022-E S G O .68 on 20 O cber 222. D ow nladed fom","PeriodicalId":406851,"journal":{"name":"Translational research/biomarkers","volume":"24 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121944431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-01DOI: 10.1136/ijgc-2022-esgo.895
R. M. Macías, Nicolas Robillard, T. Bruneau, Coronado Pluvio, Mélanie Boulhic, M. L. Frére-Belda, I. Stanković, M. Ángeles, E. Mery, P. Rigolet, C. Badoual, P. Mathevet, A. Bats, V. Taly, D. Veyer, F. Lécuru, H. Péré
{"title":"2022-RA-1480-ESGO TRANSLACOL project: digital-PCR human papilloma virus (HPV) detection for recurrence prediction in early cervical cancer patients without pelvic lymph node invasion","authors":"R. M. Macías, Nicolas Robillard, T. Bruneau, Coronado Pluvio, Mélanie Boulhic, M. L. Frére-Belda, I. Stanković, M. Ángeles, E. Mery, P. Rigolet, C. Badoual, P. Mathevet, A. Bats, V. Taly, D. Veyer, F. Lécuru, H. Péré","doi":"10.1136/ijgc-2022-esgo.895","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.895","url":null,"abstract":"","PeriodicalId":406851,"journal":{"name":"Translational research/biomarkers","volume":"40 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131956545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-01DOI: 10.1136/ijgc-2022-esgo.891
Alpana Sharma, N. Gupta, R. Khan, M. Sharma
{"title":"2022-RA-1360-ESGO Circulatory HMGB-1 as a plausible diagnostic marker in liquid biopsy of cervical cancer","authors":"Alpana Sharma, N. Gupta, R. Khan, M. Sharma","doi":"10.1136/ijgc-2022-esgo.891","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.891","url":null,"abstract":"","PeriodicalId":406851,"journal":{"name":"Translational research/biomarkers","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114067186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-01DOI: 10.1136/ijgc-2022-esgo.874
Yanan Kang, Yi Zhang
{"title":"2022-RA-846-ESGO Predictive value of DNA methylation markers as an invasive diagnostic tool for pathological upgrading cervical lesions","authors":"Yanan Kang, Yi Zhang","doi":"10.1136/ijgc-2022-esgo.874","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.874","url":null,"abstract":"","PeriodicalId":406851,"journal":{"name":"Translational research/biomarkers","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116723775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-01DOI: 10.1136/ijgc-2022-esgo.888
R. Ergasti, M. Q. Lim, G. Giannone, D. Ennis, I. Dye, H. Mirza, A. Fagotti, G. Scambia, I. McNeish
{"title":"2022-RA-1218-ESGO Physiologically relevant treatment models to investigate epigenetic mechanisms driving platinum resistance in ovarian high grade serous carcinoma","authors":"R. Ergasti, M. Q. Lim, G. Giannone, D. Ennis, I. Dye, H. Mirza, A. Fagotti, G. Scambia, I. McNeish","doi":"10.1136/ijgc-2022-esgo.888","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.888","url":null,"abstract":"","PeriodicalId":406851,"journal":{"name":"Translational research/biomarkers","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125171492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-01DOI: 10.1136/ijgc-2022-esgo.900
P. Cunnea, E. Christie, E. Curry, C. Kwok, A. Pandey, K. Nixon, J. Ploski, J. Krell, I. McNeish, D. Bowtell, C. Fotopoulou
{"title":"2022-RA-1608-ESGO Clinical implications of genomic intratumoural heterogeneity in high grade serous ovarian cancer","authors":"P. Cunnea, E. Christie, E. Curry, C. Kwok, A. Pandey, K. Nixon, J. Ploski, J. Krell, I. McNeish, D. Bowtell, C. Fotopoulou","doi":"10.1136/ijgc-2022-esgo.900","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.900","url":null,"abstract":"","PeriodicalId":406851,"journal":{"name":"Translational research/biomarkers","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117117188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-01DOI: 10.1136/ijgc-2022-esgo.877
F. Pagano, Flurina Anna-Carina Maria Saner, Solass Wiebke, S. Imboden, M. Mueller
{"title":"2022-RA-915-ESGO STK11 adnexal tumors: challenge of a new tumor entity","authors":"F. Pagano, Flurina Anna-Carina Maria Saner, Solass Wiebke, S. Imboden, M. Mueller","doi":"10.1136/ijgc-2022-esgo.877","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.877","url":null,"abstract":"","PeriodicalId":406851,"journal":{"name":"Translational research/biomarkers","volume":"2 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131656771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-01DOI: 10.1136/ijgc-2022-esgo.896
A. Skof, Wilbert Mbuya, R. Mcharo, L. Torres, J. France, A. Kroidl, C. Geldmacher, A. Kaufmann
{"title":"2022-RA-1502-ESGO Multiplexed biomarker detection using the QuantiGene assay in women living with HIV for cervical dysplasia detection","authors":"A. Skof, Wilbert Mbuya, R. Mcharo, L. Torres, J. France, A. Kroidl, C. Geldmacher, A. Kaufmann","doi":"10.1136/ijgc-2022-esgo.896","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.896","url":null,"abstract":"","PeriodicalId":406851,"journal":{"name":"Translational research/biomarkers","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128928486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-01DOI: 10.1136/ijgc-2022-esgo.881
A. Skof, E. Payrich, Maja Struck, S. Thies, C. Schreckenberger, J. Sehouli, A. Kaufmann
{"title":"2022-RA-1093-ESGO Validation of self-sampling use for a multiplexed biomarker assay for HPV and dysplasia detection","authors":"A. Skof, E. Payrich, Maja Struck, S. Thies, C. Schreckenberger, J. Sehouli, A. Kaufmann","doi":"10.1136/ijgc-2022-esgo.881","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.881","url":null,"abstract":"","PeriodicalId":406851,"journal":{"name":"Translational research/biomarkers","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129353953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：